Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Human interindividual variability in susceptibility to FEV1 decline from smoking.

Authors
Silver-K; Hattis-D
Source
Center for Technology, Policy and Industrial Development Massachusetts Institute of Technology, Cambridge, Massachusetts, 1990 Oct; :1-29
Link
NIOSHTIC No.
00196222
Abstract
This report was part of an extended series of studies seeking new methods for quantitative risk assessment for noncancer health effects from smoking. The data sets from two studies of the effects of smoking on forced expiratory volume in 1 second (FEV1) were reviewed. In each case the data could be adequately described with a mixture of two normal distributions in which 31 to 34% of the population was contained in a subgroup with lower average FEV1's and greater variability in observed FEV1's in comparison to standard regression model predictions. Some interindividual variability in the response to cigarette smoke appeared in both populations studied here. For the Six Cities data set, the initial estimate of interindividual variability was described by a geometric standard deviation of 1.9, expressed as the antilog. Interindividual variability in the other data set, the Tucson data set, was best described by a geometric standard deviation of 4.2. As more is learned about the human interindividual variability at various mechanistic steps on the causal pathway from cigarette smoke and/or other lung damaging agents to decline in FEV1, the extent of human interindividual variability in each individual pharmacokinetic or pharmacodynamic parameter should be less than the overall variability tentatively assessed in this study. The authors suggest that a wider use of scatter plots and other graphic displays that reveal underlying distributions would allow risk assessors to make greater use of experimental and epidemiologic data in modeling human interindividual variability.
Keywords
NIOSH-Contract; Contract-IA-U6O-CCU100929; Respiratory-system-disorders; Lung-irritants; Tobacco-smoke; Pulmonary-function-tests; Lung-function; Cigarette-smoking;
Publication Date
19901001
Document Type
Cooperative Agreement; Interagency Agreement
Funding Type
Cooperative Agreement; Interagency Agreement
Fiscal Year
1991
NTIS Accession No.
PB91-152751
NTIS Price
A03
Identifying No.
IA-U6O-CCU-100929
Priority Area
Asthma and Chronic Obstructive Pulmonary Disease; Disease and Injury; Respiratory-system-disorders;
Source Name
Center for Technology, Policy and Industrial Development Massachusetts Institute of Technology, Cambridge, Massachusetts, Interagency Agreement No. U6O-CCU100929, 29 pages, 21 references
State
MA
TOP